CFML
NKTR icon

COMPASS FINANCIAL MANAGEMENT LLC’s Nektar Therapeutics NKTR Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73 Buy
+1
New +$73 ﹤0.01% 1516

Other funds holding NKTR

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's NKTR Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 1 share worth $73. The stake represents ﹤0.01% of the portfolio and ranks #1516 among its holdings.

109 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • COMPASS FINANCIAL MANAGEMENT LLC held 1 share of Nektar Therapeutics worth $73 as of Q2 2026.
  • Nektar Therapeutics was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #1516 holding.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.